IPXL News 23.92 Impax Laboratories (IPXL)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Impax Laboratories (IPXL) 23.92 $IPXL

Impax to Sell Authorized Generic Renvela - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:14PM CDT
Impax has started shipping the authorized generic version of Sanofi's Renvela (800 mg) under its settlement agreement with the latter.

Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets

Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection

Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.

Impax introduces generic RENVELA in the market
M2 - Thu Apr 17, 5:13AM CDT
Pharmaceutical company Impax Laboratories (NasdaqGS :IPXL) reported on Wednesday the shipment of its authorised generic RENVELA (sevelamer carbonate 800 mg tablets) for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Impax Launches Authorized Generic RENVELA®
PR Newswire - Wed Apr 16, 8:10AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of authorized generic RENVELA (sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax's generics division. RENVELA is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Regulatory Update from Impax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:55PM CDT
Impax resubmitted a new drug application (NDA) for Rytary for the symptomatic treatment of Parkinson's disease (PD).

Impax Breathes New Life Into Stalled Parkinson's Drug
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors had high hopes when  Impax   filed for FDA approval of IPX066, or Rytary, an extended release version of a common Parkinson's drug therapy, in 2011. But manufacturing woes dashed the drug's chances for an FDA approval, and ultimately...

Impax Pharmaceuticals Resubmits New Drug Application for RYTARY(TM) (Carbidopa and Levodopa) Extended-Release Capsules (IPX066)
PR Newswire - Fri Apr 11, 6:15AM CDT
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease (PD).

Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:37AM CDT
Mallinckrodt plc as the company saw its shares rise more than 5% on the day.

Pacira and Patheon Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:10PM CDT
Pacira has signed a strategic co-production partnership deal with Patheon.

Additional Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:20PM CDT
Pacira announced additional phase III data on its lead product, Exparel.

Health Care Sector Stocks under Review -- Research on Sanofi, Impax Laboratories, Keryx Biopharma, and Rigel Pharma
PR Newswire - Tue Apr 08, 12:59PM CDT
The trading session on Monday, April 07, 2014 ended on a lower note as the S&P 500 finished the session 1.08% lower at 1,845.04 and the NASDAQ Composite closed at 4,079.75, down 1.16%. The Dow Jones Industrial Average finished at 16,245.87, down 1.02%. During the session, nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 664.68, down 1.06%, and the same has declined 2.85% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free technical research on SNY, IPXL, KERX and RIGL can be downloaded upon signing up at:

Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2014 Financial Results
PR Newswire - Mon Apr 07, 7:15AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 4:30 p.m., Eastern Time on May 1, 2014.

Actavis Up Slightly on Silom Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:56PM CDT
Actavis acquired Thailand-based generic company, Silom Medical Company.

Impax Laboratories Announces the Alignment of Quality and Manufacturing Operations Under the Leadership of Jeffrey D. Nornhold
PR Newswire - Wed Apr 02, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Jeffrey D. Nornhold has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the Company's Senior Vice President, Global Quality Affairs since March 2011.

Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:00PM CDT
Pacira Pharma's shares gained 10.7% after the FDA approved of an additional manufacturing suite (Suite C) for Exparel.

Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories
PR Newswire - Wed Mar 19, 7:41AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 688.96, up 1.17%, and the same has advanced 1.47% in the last one month. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc. (NASDAQ: IPXL). Free technical research on KERX, RIGL, SNY and IPXL can be downloaded upon signing up at:

Impax Laboratories Has Returned 18.4% Since SmarTrend Recommendation (IPXL)
Comtex SmarTrend(R) - Mon Mar 17, 9:23AM CDT
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on February 19th, 2014 at $24.00. In approximately 4 weeks, Impax Laboratories has returned 18.39% as of today's recent price of $28.42.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading